Daniel Young, MD
Infectious Disease · Bentonville, ARNPI 1265656425
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,870 of the $65,447 with a category attached, or 71.6%. Gilead accounts for 88.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $24,800, more than ten times the $1,372 reported in 2019. Among infectious disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $113.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$58K
- Viiv Healthcare Company$2K
- AbbVie$1K
- Insmed, Inc.$1K
- Merck$887
- Cumberland Pharmaceuticals, Inc.$762
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$46,87072%
- Travel & lodging$6,89511%
- Food & beverage$11,48318%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 172 | $57,940 |
| Viiv Healthcare Company | 96 | $1,715 |
| AbbVie(2 entities) | 96 | $1,440 |
| Insmed, Inc. | 64 | $1,354 |
| Merck | 58 | $887 |
| Cumberland Pharmaceuticals, Inc. | 20 | $762 |
| La Jolla Pharmaceutical Company | 22 | $342 |
| Astellas Pharma US Inc | 8 | $242 |
| Paratek Pharmaceuticals, Inc. | 10 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Shionogi Inc | 4 | $89 |
| Johnson & Johnson | 6 | $86 |
| Pfizer | 4 | $74 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $65 |
| Mayne Pharma Commercial LLC | 3 | $60 |
| Melinta Therapeutics, LLC | 2 | $50 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Kerecis Limited | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,447 in reported general payments places this provider in the 95th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 123 | $529,920 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $200,278 |
| Daptomycin | 87 | $164,846 |
| DovatoDolutegravir Sodium/Lamivudine | 50 | $145,993 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $58,820 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 11 | $51,053 |
| TivicayDolutegravir Sodium | 23 | $50,295 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $24,225 |
| PifeltroDoravirine | 11 | $20,515 |
| ErtapenemErtapenem Sodium | 32 | $16,616 |
| Vancomycin Hcl | 63 | $14,320 |
| CeftriaxoneCeftriaxone Sodium | 103 | $10,217 |
| Cefazolin Sodium | 81 | $7,028 |
| Meropenem | 21 | $6,080 |
| Cefepime Hcl | 27 | $5,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $57,940 | $554,145134 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $1,715 | $255,10889 claims |
| Insmed, Inc.Arikayce | $1,354 | $200,27813 claims |
| MerckPifeltro | $887 | $20,51511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 infectious disease providers in Arkansas.
Other infectious disease in Bentonville
- James NewtonFayetteville$15K
- Stephen HenniganFayetteville$9K
- Andrew EbersRogers$2K
- Jeremy BariolaLittle Rock$2K
- Kevin DavisFort Smith$2K
- Naveen PatilLittle Rock$1K
- Amanda NovackNorth Little Rock$1K
- Katherine FerrenLittle Rock$1K
- Mary BurgessLittle Rock$1K
- Jason HammackSherwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.